Stifel Nicolaus analyst Annabel Samimy has reiterated their bullish stance on TRVI stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Annabel Samimy’s rating is based on the promising results from Trevi Therapeutics’ Phase 2b CORAL study of Haduvio for chronic cough associated with idiopathic pulmonary fibrosis (IPF-CC). The study demonstrated significant dose-dependent reductions in cough frequency, with a rapid onset of effect by the second week and sustained improvements throughout the trial. These results highlight Haduvio’s unique mechanism of action and its potential as a first-in-class treatment for this challenging condition.
Furthermore, the safety profile of Haduvio was consistent with previous trials, showing low rates of serious adverse events and discontinuations, which supports its potential for broader use. Trevi Therapeutics is strategically positioned to advance Haduvio into pivotal trials, targeting a high-value market with no current FDA-approved treatments. The company’s focus on commercialization and potential expansion into other related indications adds to the attractiveness of the stock, justifying the Buy rating.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $23.00 price target.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TRVI in relation to earlier this year.